Drug class profile · refreshed daily from federal data

Nitrofuran Antibacterial

9 molecules in this class, $9.8M combined CY2024 Part D spend across 4K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 15 Oct 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Nitrofuran Antibacterial class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 9tracked in Part D
CY24 Part D spend: $9.8Mcombined across class
Total Rx claims: 4K2K unique beneficiaries
Generic mfrs (active): 21across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

01

Nitrofurantoin

4K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2011-03-24

9 generic mfrs 2 plans require PA

Low NADAC$0.153

→

Avg plan cost$0.688

Part D spend $9.8M 5× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

02

Nitrofurantion

— Part D claims (CY24) · First FDA approval: 2016-04-15

Brand-only (no generics) 0 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

03

Nitrofurantion Macrocrystals

— Part D claims (CY24) · First FDA approval: 2010-09-27

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

04

Nitrofurantoin (Macrocrystals)

— Part D claims (CY24) · First FDA approval: 2023-05-12

Brand-only (no generics) 0 plans require PA

Low NADAC$0.165

→

Avg plan cost$0.199

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

05

Nitrofurantoin (Monohydrate and Macrocrystals)

Brand: NITROFURANTOIN · — Part D claims (CY24) · First FDA approval: 2005-04-06

Brand-only (no generics) 0 plans require PA

Low NADAC$0.296

→

Avg plan cost$0.296

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

06

Nitrofurantoin Oral Suspension

— Part D claims (CY24) · First FDA approval: 2024-06-10

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

07

Nitrofurantoin and Macrocrystal

— Part D claims (CY24) · First FDA approval: 2022-11-22

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

08

Nitrofurantoin and Macrocrystalline

Brand: Macrobid · — Part D claims (CY24) · First FDA approval: 2011-05-25

12 generic mfrs

Low NADAC$0.296

→

Avg plan cost$0.309

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

09

Nitrofurantoin and Macrocrystals

Brand: Nitrofurantoin · — Part D claims (CY24) · First FDA approval: 2017-05-25

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

Related questions.

Q&A librarySourced · reviewed quarterly

pricingWhat is NADAC?pricingIs NADAC the same as my PBM cost?pricingWhat is spread pricing?pricingWhat is a NADAC pass-through PBM contract?pricingWhat's the difference between AWP, MAC, and NADAC?pricingWhat is a dispensing fee in a PBM contract?

Browse all canonical questions →